BDBM145276 US8952169, 55

SMILES: CS(=O)(=O)NC(=O)c1ccc(OCC2C3CC4CC(C3)CC2C4)c(c1)C1CC1

InChI Key: InChIKey=XXRRNFFJNMKKHJ-UHFFFAOYSA-N

Data: 2 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 145276   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Sodium channel protein type 9 subunit alpha (Homo sapiens (Human))	BDBM145276 (US8952169, 55) Show SMILES CS(=O)(=O)NC(=O)c1ccc(OCC2C3CC4CC(C3)CC2C4)c(c1)C1CC1 |TLB:12:13:15:17.18.19,THB:13:21:17:15.14.19,13:14:17:21.20.22,20:21:15:17.18.19,20:18:15:21.13.22,(7.75,1.73,;6.42,2.5,;5.65,3.84,;7.19,3.84,;5.08,1.73,;3.75,2.5,;3.75,4.04,;2.41,1.73,;1.08,2.5,;-.25,1.73,;-.25,.19,;-1.59,-.58,;-2.92,.19,;-4.25,-.58,;-5.58,.19,;-6.92,-.58,;-6.92,-2.12,;-7.75,-4.02,;-6.35,-3.37,;-6.34,-.97,;-5.15,-4.04,;-4.25,-2.12,;-5.58,-2.89,;1.08,-.58,;2.41,.19,;1.08,-2.12,;.31,-3.45,;1.85,-3.45,)| Show InChI InChI=1S/C22H29NO4S/c1-28(25,26)23-22(24)16-4-5-21(19(11-16)15-2-3-15)27-12-20-17-7-13-6-14(9-17)10-18(20)8-13/h4-5,11,13-15,17-18,20H,2-3,6-10,12H2,1H3,(H,23,24)	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	3.10	n/a	n/a	n/a	n/a	n/a	37
Xenon Pharmaceuticals Inc.; Genentech, Inc. US Patent					Assay Description Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...				US Patent US8952169 (2015) BindingDB Entry DOI: 10.7270/Q2M04445
					More data for this Ligand-Target Pair
Sodium channel protein type 9 subunit alpha (Homo sapiens (Human))	BDBM145276 (US8952169, 55) Show SMILES CS(=O)(=O)NC(=O)c1ccc(OCC2C3CC4CC(C3)CC2C4)c(c1)C1CC1 |TLB:12:13:15:17.18.19,THB:13:21:17:15.14.19,13:14:17:21.20.22,20:21:15:17.18.19,20:18:15:21.13.22,(7.75,1.73,;6.42,2.5,;5.65,3.84,;7.19,3.84,;5.08,1.73,;3.75,2.5,;3.75,4.04,;2.41,1.73,;1.08,2.5,;-.25,1.73,;-.25,.19,;-1.59,-.58,;-2.92,.19,;-4.25,-.58,;-5.58,.19,;-6.92,-.58,;-6.92,-2.12,;-7.75,-4.02,;-6.35,-3.37,;-6.34,-.97,;-5.15,-4.04,;-4.25,-2.12,;-5.58,-2.89,;1.08,-.58,;2.41,.19,;1.08,-2.12,;.31,-3.45,;1.85,-3.45,)| Show InChI InChI=1S/C22H29NO4S/c1-28(25,26)23-22(24)16-4-5-21(19(11-16)15-2-3-15)27-12-20-17-7-13-6-14(9-17)10-18(20)8-13/h4-5,11,13-15,17-18,20H,2-3,6-10,12H2,1H3,(H,23,24)	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	9	n/a	n/a	n/a	n/a	7.4	25
Xenon Pharmaceuticals Inc.; Genentech, Inc. US Patent					Assay Description Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...				US Patent US8952169 (2015) BindingDB Entry DOI: 10.7270/Q2M04445
					More data for this Ligand-Target Pair